Ovarian Cancer

Home / Ovarian Cancer

 Pam Boruff In Remission

Live Well Nebraska HIPEC Article in Omaha World-Herald,  March 2018 

Pam Boruff is in remission after battling cancer of the abdominal lining. She is a patient of Dr. Brian Loggie at Creighton University Medical Center. Dr. Loggie treated Pam using hyperthermic intraperitoneal chemotherapy or HIPEC. Dr. Loggie helped to pioneer this treatment in the 1990 and he is hoping that new research studies will help this treatment become a more common practice that will help to extend the lives of many cancer patients with cancer in the abdominal area.

Schedule a Conversation with Dr. Brian Loggie

Read the Article:
Anderson, Julie. “Omaha Docs Hope ‘Hot Chemo’ Trial Will Lead to Wider Use of Treatment.” Omaha.com, 5 Mar. 2018, www.omaha.com/livewellnebraska/plus/omaha-docs-hope-hot-chemo-trial-will-lead-to-wider/article_d5ed79b2-a94f-597e-97fc-cfcb0dbca6ff.html.

News For Advanced Ovarian Cancer Treatment , January 18, 2018

A trial study conducted in participating centers in the Netherlands and Belgium concluded that ”the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone” in patients with stage III epithelial ovarian cancer. 245 patients in this study were randomized between interval cytoreductive surgery alone and interval cytoreductive surgery with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Cytoreductive surgery is a surgical procedure to remove all visible tumors.The HIPEC procedure is designed to be used after Cytoreductive surgery in an attempt to kill any remaining cancer cells with a heated sterile solution–containing a chemotherapeutic. The study found that patients who underwent cytoreductive surgery with HIPEC had a median overall survival of 45.7 months.  

To read more about this study, view the abstract on the The New England Journal of Medicine.

Cancer Treatment Centers of America Offers Heated Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for Ovarian Cancer Patients, June 20, 2019

In March, the National Comprehensive Cancer Network (NCCN) released updated guidelines stating that Heated Intraperitoneal Chemotherapy (HIPEC) using the chemotherapy drug cisplatin can be considered with debulking surgery for stage III epithelial ovarian cancer patients. The guidelines, and the research supporting them, show that HIPEC has gained recognition as a promising and innovative procedure for an advanced and complex disease.

To read more about this study, read the full article on Yahoo News.

Patients Share Their Stories

Lori’s Story

Lori’s Story

Lori Moon, of Lincoln, was treated with HIPEC during surgery to treat Ovarian Cancer. She is a Patient of Dr. Thomas Minor of Rhode Island Hospital. Read her story and watch the news video.

Read More

Surgery for Ovarian Cancer

The first line in the treatment and diagnosis of ovarian cancer at Cancer Treatment Centers of America® (CTCA) is often surgery. Our goal during ovarian cancer surgery is to locate and remove all visible signs of cancer in a process called debulking.

During surgery for ovarian cancer, our gynecologic oncologists may also collect samples from a variety of tissues to test for the presence of cancer in order to determine whether the cancer has spread, or metastasized. They also work with other members of your care team to anticipate and help manage side effects that may result from surgery.

Whether an ovarian cancer patient is a candidate for surgery depends on several factors, including preexisting medical conditions, nutritional status, whether the patient has undergone previous surgeries to treat the cancer, and, in the case of a recurrence, when the last cancer treatment was performed.

Read More

Schedule a Conversation with a Surgeon

Cancer that forms in tissues of the ovary. Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells).

Despite numerous recent advances in chemotherapy, the overall chance of chemotherapy being curative is still low, and the side effects are difficult for the patient to endure. However, when these cancers are confined to the peritoneal cavity, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) becomes an option for candidate patients.

Many of the cancers treated with HIPEC are diseases treated by multiple disciplines in medicine and surgery. It is important that patients discuss HIPEC therapy with their oncologists and surgeon who can guide their therapy appropriately. Sometimes a referral to a Surgical Oncologist or Gynecological Oncologist performing HIPEC is helpful and necessary early at the time of diagnosis. These doctors can help determine if a patient can benefit from HIPEC and then formulate a comprehensive treatment plan.

Dr. Dennis Chi: What Ovarian Cancer Patients Should Know

Dr. David Bartlett discusses the treatment of ovarian cancer with HIPEC


Dr. Armando Sardi: HIPEC Treatment of Late Stage Abdominal Cancer

VCU Massey Cancer Center now offering HIPEC for advanced abdominal cancers

HIPEC Treatment for Ovarian Cancer - Drs. Armando Sardi and Teresa Diaz-Montes - Mercy

Dr. Lewin on the Addition of HIPEC to Interval Cytoreductive Surgery in Ovarian Cancer